FR2514644B1 - - Google Patents

Info

Publication number
FR2514644B1
FR2514644B1 FR8119607A FR8119607A FR2514644B1 FR 2514644 B1 FR2514644 B1 FR 2514644B1 FR 8119607 A FR8119607 A FR 8119607A FR 8119607 A FR8119607 A FR 8119607A FR 2514644 B1 FR2514644 B1 FR 2514644B1
Authority
FR
France
Prior art keywords
haloallylate
levallorphan
opiates
bromine
iodine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8119607A
Other languages
English (en)
French (fr)
Other versions
FR2514644A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to FR8119607A priority Critical patent/FR2514644A1/fr
Priority to IL66853A priority patent/IL66853A/xx
Priority to US06/422,568 priority patent/US4489079A/en
Priority to ZA827063A priority patent/ZA827063B/xx
Priority to AU88922/82A priority patent/AU559451B2/en
Priority to JP57177719A priority patent/JPS5874608A/ja
Priority to DE8282401876T priority patent/DE3269082D1/de
Priority to EP82401876A priority patent/EP0077723B1/fr
Priority to AT82401876T priority patent/ATE17942T1/de
Priority to NZ202210A priority patent/NZ202210A/en
Publication of FR2514644A1 publication Critical patent/FR2514644A1/fr
Application granted granted Critical
Publication of FR2514644B1 publication Critical patent/FR2514644B1/fr
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FR8119607A 1981-10-19 1981-10-19 Composition pharmaceutique a action antagoniste peripherique des opiaces Granted FR2514644A1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR8119607A FR2514644A1 (fr) 1981-10-19 1981-10-19 Composition pharmaceutique a action antagoniste peripherique des opiaces
IL66853A IL66853A (en) 1981-10-19 1982-09-22 Pharmaceutical compositions comprising levallorphan derivatives
US06/422,568 US4489079A (en) 1981-10-19 1982-09-24 Pharmaceutical compositions having a peripheral antagonistic action with respect to opiates
ZA827063A ZA827063B (en) 1981-10-19 1982-09-27 Pharmaceutical compositions having a peripheral antagonistic action with respect to opiates
AU88922/82A AU559451B2 (en) 1981-10-19 1982-09-30 Haloallylate of levallorphan
JP57177719A JPS5874608A (ja) 1981-10-19 1982-10-12 アヘン製剤に関して末梢「きつ」抗作用を有する製薬組成物
DE8282401876T DE3269082D1 (en) 1981-10-19 1982-10-13 Pharmaceutical composition with an antagonist peripheric action of the narcotics
EP82401876A EP0077723B1 (fr) 1981-10-19 1982-10-13 Composition pharmaceutique à action antagoniste périphérique des narcotiques
AT82401876T ATE17942T1 (de) 1981-10-19 1982-10-13 Pharmazeutische zusammensetzung mit einer antagonistischen peripheren wirkung der narkotischen mittel.
NZ202210A NZ202210A (en) 1981-10-19 1982-10-18 Pharmaceutical compositions containing haloallylates of levallorphan

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8119607A FR2514644A1 (fr) 1981-10-19 1981-10-19 Composition pharmaceutique a action antagoniste peripherique des opiaces

Publications (2)

Publication Number Publication Date
FR2514644A1 FR2514644A1 (fr) 1983-04-22
FR2514644B1 true FR2514644B1 (enExample) 1984-04-20

Family

ID=9263165

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8119607A Granted FR2514644A1 (fr) 1981-10-19 1981-10-19 Composition pharmaceutique a action antagoniste peripherique des opiaces

Country Status (10)

Country Link
US (1) US4489079A (enExample)
EP (1) EP0077723B1 (enExample)
JP (1) JPS5874608A (enExample)
AT (1) ATE17942T1 (enExample)
AU (1) AU559451B2 (enExample)
DE (1) DE3269082D1 (enExample)
FR (1) FR2514644A1 (enExample)
IL (1) IL66853A (enExample)
NZ (1) NZ202210A (enExample)
ZA (1) ZA827063B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2547820B1 (fr) * 1983-06-24 1986-04-18 Midy Spa Antagonistes peripheriques des opiaces
US5624958A (en) * 1987-12-31 1997-04-29 Isaacs; Charles E. Disinfecting contact lenses
US5552406A (en) * 1994-06-17 1996-09-03 The Mclean Hospital Corporation Method for treating pain and brain perfusion abnormalities using mixed opioid agonist-antagonists
DE19752080A1 (de) * 1997-11-25 1999-07-29 Karlsruhe Forschzent Verfahren zur Herstellung eines mehrkomponentigen, oxidischen Keramikpulvers
WO2001042207A2 (en) * 1999-11-29 2001-06-14 Adolor Corporation Novel methods for the treatment and prevention of ileus
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
EP2236161A1 (en) * 2001-10-18 2010-10-06 Nektar Therapeutics Polymer conjugates of opioid antagonists
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
HRP20140361T1 (hr) * 2003-12-16 2014-05-23 Nektar Therapeutics Monodisperzne smjese pegiliranog naloksola
AU2008286979B2 (en) 2007-08-09 2013-03-28 Rensselaer Polytechnic Institute Quaternary opioid carboxamides
AU2010326676B2 (en) 2009-12-04 2013-03-14 Alkermes Pharma Ireland Limited Morphinan derivatives for the treatment of drug overdose
JP5964809B2 (ja) 2010-03-22 2016-08-03 レンセラール ポリテクニック インスティチュート オピオイド受容体リガンドとしてのカルボキサミド基を含有するモルヒネ誘導体
PL3446565T3 (pl) 2010-08-23 2024-04-02 Alkermes Pharma Ireland Limited Sposoby leczenia przyrostu masy ciała wywołanego lekami przeciwpsychotycznymi
RS56181B1 (sr) 2011-06-29 2017-11-30 Alkermes Inc Periferno delujuća opioidna jedinjenja
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
WO2014190270A1 (en) 2013-05-24 2014-11-27 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US9656961B2 (en) 2013-05-24 2017-05-23 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Also Published As

Publication number Publication date
AU559451B2 (en) 1987-03-12
NZ202210A (en) 1985-03-20
IL66853A (en) 1985-08-30
DE3269082D1 (en) 1986-03-27
ZA827063B (en) 1983-07-27
ATE17942T1 (de) 1986-02-15
IL66853A0 (en) 1982-12-31
EP0077723A1 (fr) 1983-04-27
JPS5874608A (ja) 1983-05-06
AU8892282A (en) 1983-04-28
US4489079A (en) 1984-12-18
FR2514644A1 (fr) 1983-04-22
EP0077723B1 (fr) 1986-02-12

Similar Documents

Publication Publication Date Title
AU559451B2 (en) Haloallylate of levallorphan
EG17753A (en) Novel pharmacological compounds
PH23778A (en) Labdan compounds,pharmaceutical compositions and use
ES8403897A1 (es) Procedimiento para la fabricacion de nuevos derivados de la amino-3 quinuclidina
PH16119A (en) New hydroxypropyl-triazole compound,their composition and medicinal use
IL78691A (en) Quinolylglycinamide derivatives,their preparation and pharmaceutical compositions containing them
PH19042A (en) Nitro aliphatic compounds,its pharmaceutical composition and use thereof
ES8501763A1 (es) "procedimiento para la fabricacion de derivados de la tetrahidro-5.6.7.7. 4h-tieno (3, 2-c) piridinona-2
IL60323A0 (en) Pseudotrisaccharide compounds,their preparation and their medicinal use
DE3362260D1 (en) (-)-15-deoxyspergualin, a process for the preparation of the same, and a pharmaceutical composition containing the same
AU601583B2 (en) Protected cyclopantanols
HUT41022A (en) Process for preparing 2-halogen-6-methyl-ergol-9-ene derivatives and acid additional salts thereof
FR2380281A1 (fr) Nouvelles imidazo(1,5-b)-pyridazines utiles comme medicaments
FR2423491A1 (fr) Composes heterocycliques azotes, en particulier n-imidazolylamino-iso-indolines, et medicaments qui en contiennent
DE3660959D1 (de) Benz-trisubstituted 2-aminotetralins
IL61769A0 (en) 2-phenylamino-imidazolines-(2),their preparation and pharmaceutical compositions containing them
EP0295582A3 (en) Process for the preparation of largely perfluorinated alkyl compounds containing chlorine, bromine or iodine as well as ether oxygen and perfluoroalkyl compounds containing chlorine, bromine or iodine as well as ether oxygen
FR2474863B1 (enExample)
JPS5436282A (en) Preparation of substituted piperazine
ES540693A0 (es) Un procedimiento de preparar sales quinato de alfa-2-piperi-dinil-2,8-bis(trifluorometil)-4-quinolino-metanol
SU1125965A1 (ru) Трехкомпонентная фторидная солевая смесь
ES482083A1 (es) Un procedimiento para la preparacion de un derivado de teta-hidro-2h-benzo-c-pirrol.
CS330884A2 (en) Zpusob vyroby 2-alkythio-1-aminoalkyl-5-oxo-2-pyrrolin-3-karbonitrilu

Legal Events

Date Code Title Description
ST Notification of lapse